LXRX
Lexicon Pharmaceuticals Inc.
$2.06
-$0.10(-4.63%)
55
Overall
60
Value
60
Tech
47
Quality
Market Cap
$461.52M
Volume
3.07M
52W Range
$0.62 - $2.53
Target Price
$3.52
Order:
Income Statement
| Metric | Trend | Chart | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec | 2025 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $83.3M | $91.5M | $62.9M | $321.6M | $23.4M | $298.0K | $139.0K | $1.1M | $6.0M | $49.8M | ||
| Total Revenue | $83.3M | $91.7M | $63.2M | $322.1M | $24.0M | $298.0K | $139.0K | $1.2M | $31.1M | $49.8M | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | -- | $1.9M | $2.5M | $3.2M | $1.9M | -- | -- | $85.0K | $616.0K | $274.0K | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $83.3M | $89.8M | $60.7M | $318.8M | $22.1M | $298.0K | $139.0K | $1.1M | $30.5M | $49.5M | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $220.5M | $222.3M | $166.5M | $180.6M | $204.4M | $87.4M | $100.9M | $186.0M | $243.2M | $106.8M | ||
| Research & Development | $178.2M | $152.2M | $100.2M | $91.9M | $153.6M | $55.0M | $52.8M | $58.9M | $84.5M | $61.1M | ||
| Research Expense | $178.2M | $152.2M | $100.2M | $91.9M | $153.6M | $55.0M | $52.8M | $58.9M | $84.5M | $61.1M | ||
| Selling, General & Administrative | $43.0M | $66.1M | $63.8M | $56.8M | $47.2M | $32.3M | $48.1M | $114.0M | $143.1M | $37.3M | ||
| General & Administrative Expenses | $43.0M | $66.1M | $63.8M | $56.8M | $47.2M | $32.3M | $48.1M | $114.0M | $143.1M | $37.3M | ||
| Amortization | -- | -- | -- | -- | -- | -- | $44.5M | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | -- | -- | -- | $2.8M | $13.1M | $15.6M | $8.3M | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-137.2M | $-130.6M | $-103.3M | $141.4M | $-47.8M | $-87.1M | $-100.8M | $-171.8M | $-197.1M | $-48.9M | ||
| EBITDA | $-132.3M | $-124.7M | $-94.8M | $148.4M | $-41.1M | $-86.7M | $-98.0M | $-179.5M | $-195.1M | $-47.8M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | $6.6M | $7.0M | $20.8M | $20.7M | $14.5M | $802.0K | $2.8M | -- | $15.6M | -- | ||
| Intinc | -- | -- | -- | -- | -- | -- | -- | -- | $12.3M | -- | ||
| Net Non-Operating Interest Income/Expense | $-6.6M | $-7.0M | $-20.8M | $-20.7M | $-14.5M | $-802.0K | $1.2M | -- | $-3.3M | -- | ||
| Other Income/Expense | $-2.3M | $-2.1M | $-3.9M | $-3.9M | $-2.7M | $-432.0K | $-1.7M | $-7.8M | $-12.4M | $-7.1M | ||
| Other Special Charges | $2.3M | $2.1M | $3.9M | $3.9M | $4.3M | $432.0K | $1.7M | $7.8M | $12.4M | $7.1M | ||
| SPECIAL ITEMS | ||||||||||||
| Special Income Charges | -- | -- | -- | $-28.6M | -- | -- | -- | -- | -- | -- | ||
| Impairment of Capital Assets | -- | -- | -- | $28.6M | -- | -- | -- | -- | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-134.9M | $-128.7M | $-99.8M | $144.8M | $-44.0M | $-87.0M | $-99.2M | $-181.8M | $-197.5M | $-50.1M | ||
| Pre-Tax Income | $-141.4M | $-135.7M | $-120.5M | $124.1M | $-58.6M | $-87.8M | $-101.9M | $-177.1M | $-231.4M | $-100.0M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | -- | $-12.7M | -- | $-6.0M | -- | -- | -- | $-4.7M | $2.9M | $195.0K | ||
| NET INCOME | ||||||||||||
| Net Income | $-141.4M | $-123.0M | $-120.5M | $130.1M | $-58.6M | $-87.8M | $-101.9M | $-177.1M | $-200.4M | $-50.3M | ||
| Net Income (Continuing Operations) | $-141.4M | $-123.0M | $-120.5M | $130.1M | $-58.6M | $-87.8M | $-101.9M | $-177.1M | $-200.4M | $-50.3M | ||
| Net Income (Discontinued Operations) | $-141.4M | $-123.0M | $-120.5M | $130.1M | $-58.6M | $-87.8M | $-101.9M | $-177.1M | $-200.4M | $-50.3M | ||
| Net Income (Common Stockholders) | $-141.4M | $-123.0M | $-120.5M | $130.1M | $-58.6M | $-87.8M | $-101.9M | $-177.1M | $-200.4M | $-50.3M | ||
| Normalized Income | $-91.9M | $-148.3M | $-95.2M | $146.7M | $-44.7M | $-69.3M | $-80.5M | -- | -- | $-99.0M | ||
| TOTALS | ||||||||||||
| Total Expenses | $220.5M | $224.2M | $169.0M | $183.9M | $206.3M | $87.4M | $100.9M | $186.1M | $243.8M | $107.1M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $103.9M | $105.2M | $105.8M | $106.2M | $110.8M | $145.7M | $165.7M | $221.1M | $320.0M | $363.1M | ||
| Average Shares Outstanding (Diluted) | $103.9M | $105.2M | $105.8M | $116.7M | $110.8M | $145.7M | $165.7M | $221.1M | $320.0M | $363.1M | ||
| Shares Outstanding | $104.3M | $105.6M | $106.3M | $107.0M | $144.4M | $444.2M | $188.7M | $246.2M | $361.5M | $423.7M | ||
| Basic EPS | $-1.36 | $-1.23 | $-1.14 | $1.23 | $-0.53 | $-0.60 | $-0.62 | $-0.80 | $-0.63 | $-0.14 | ||
| Basic EPS (Continuing Operations) | $-1.36 | $-1.23 | $-1.14 | $1.23 | $-0.53 | $-0.60 | $-0.62 | $-0.80 | $-0.63 | $-0.14 | ||
| Diluted EPS | $-1.36 | $-1.23 | $-1.14 | $1.16 | $-0.53 | $-0.60 | $-0.62 | $-0.80 | $-0.63 | $-0.14 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | $1.16 | $-0.53 | $-0.60 | -- | $-0.80 | $-0.63 | $-0.14 | ||
| OTHER METRICS | ||||||||||||
| Other Gand A | $43.0M | $66.1M | $63.8M | $56.8M | $47.2M | $32.3M | $48.1M | $114.0M | $143.1M | $37.3M | ||
| Other Impairment Of Capital Assets | -- | -- | -- | $28.6M | $1.6M | -- | -- | -- | -- | -- | ||
| Rent And Landing Fees | -- | -- | -- | -- | -- | -- | $-1.1M | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | LXRX | $2.06 | -4.6% | 3.07M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Lexicon Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW